Compare OLN & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLN | SRPT |
|---|---|---|
| Founded | 1892 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.5B |
| IPO Year | 1994 | 2000 |
| Metric | OLN | SRPT |
|---|---|---|
| Price | $25.04 | $15.22 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 13 | 29 |
| Target Price | $25.23 | ★ $25.85 |
| AVG Volume (30 Days) | 1.8M | ★ 2.6M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.92% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.88 |
| Revenue | ★ $6,780,800,000.00 | $2,198,237,000.00 |
| Revenue This Year | $2.57 | N/A |
| Revenue Next Year | $3.51 | N/A |
| P/E Ratio | ★ N/A | $5.21 |
| Revenue Growth | 3.68 | ★ 15.58 |
| 52 Week Low | $18.08 | $10.42 |
| 52 Week High | $30.46 | $25.32 |
| Indicator | OLN | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 44.21 | 34.08 |
| Support Level | $22.82 | N/A |
| Resistance Level | $26.84 | $23.54 |
| Average True Range (ATR) | 0.85 | 0.73 |
| MACD | -0.09 | -0.06 |
| Stochastic Oscillator | 41.51 | 15.56 |
Olin Corp manufactures and sells a variety of chemicals and chemical-based products. The company organizes itself into three segments based on the product type. The Chlor alkali products and Vinyls segment, which generates the majority of revenue, sells chlorine and caustic soda, which are used in a variety of industries including cosmetics, textiles, crop protection, and fire protection products. The Epoxy segment sells epoxy resins used in paints and coatings. The Winchester segment sells sporting ammunition and ammunition accessories under the Winchester brand. The majority of revenue comes from the United States.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.